Novo Nordisk's Direct Listing Talk Won't Fix the Pipeline — But It Will Re-Price the Whole GLP-1 Trade

Novo Nordisk CEO Mike Doustdar told the Financial Times in an interview published September 23, 2026 that he is open, over the longer term, to a direct listing on the New York Stock Exchange that would replace the American Depositary Receipts U.S. investors currently trade under ticker NVO. He stressed there are no active discussions — \"I start with 'maybe'\" — and that the idea has not been on the table since he became CEO last year. The U.S. accounts for more than half of the company's revenue, and the bulk of sales of Ozempic and Wegovy.

The comment arrived two days after a Bloomberg-flagged investor day on September 21, where Doustdar's \"more than five blockbuster drugs by 2030\" plan was met with a 7%-plus share slide as the market judged it light on near-term catalysts. The Q2 2026 print on August 4 had already shown a 22% constant-currency drop in U.S. Wegovy injectable sales — making the \"we need to be more visible to U.S. investors\" framing more about re-rating than re-financing.

The most striking number in the entire GLP-1 trade is not Eli Lilly's $1.1 trillion market cap. It is that Novo Nordisk — with $46 billion of trailing revenue, an 80.6% gross margin, and a 43.1% TTM operating margin — trades at a 9.9x trailing P/E. Eli Lilly, with $79.7 billion of TTM revenue and a 49.7% operating margin, trades at 39.2x. The market is pricing Novo at roughly one-quarter of the multiple it gives Lilly, despite Novo's earnings base being only 1.4x smaller. On EV/EBITDA, the gap narrows but persists: Novo at 7.2x versus Lilly at 26.5x.

The discount has three plausible drivers, only one of which a direct listing fixes. One — pipeline fear — is real: CagriSema's February 2026 head-to-head miss versus tirzepatide (22.7% vs. 25.5% weight loss) reset the bull case. Two — supply-share loss to Lilly — is real: LSEG data cited in the FT show Zepbound set to outsell Wegovy by more than $7 billion in 2026. Three — the ADR friction that pushes U.S. generalist investors into Lilly — is structural, and a direct listing attacks it directly. Of the three, only the third responds to a ticker change.

Novo Nordisk shares have fallen more than 70% from their 2023 peak, when it briefly became Europe's most valuable listed firm with a market value above EUR 600 billion. The TTM revenue line is still growing — DKK 329.4 billion through June 30, 2026 — but Q2 2026 sales of DKK 78.5 billion were only 2% higher than a year earlier at reported rates, and the U.S. Wegovy injectable franchise contracted sharply. Forward earnings momentum has flipped: analysts now sit at 3 Buy, 11 Hold, and a $46.80 average target on the ADR — modest upside versus the $39.40 print. The market has effectively stopped pricing Novo as a growth name.

Compare the simpler reform: a buyback. Novo Nordisk is running a DKK 15 billion repurchase program through February 4, 2027 — about $2.3 billion at current rates — and had retired 34.2 million B shares by September 18, 2026 at an average DKK 281.79. That is supply removal, not demand expansion. A direct listing does the opposite: it widens the eligible buyer pool to every passive index fund, every retail broker, and every quant strategy that currently excludes ADR-converted names. The U.S. institutional ownership rate on Novo sits at 9.9%; on Lilly, 85.3%. Closing half that gap is a re-rating event in its own right.

Here is the catch that makes this a slower-moving story than the FT headline suggests. Novo Nordisk's share capital is split between unlisted A shares (held entirely by Novo Holdings A/S, which is itself wholly owned by the Novo Nordisk Foundation) and listed B shares trading on Nasdaq Copenhagen and as ADRs on the NYSE. Each A share carries 100 votes; each B share carries 10. Per the Foundation's Articles of Association, the A shares cannot be divested. The Foundation controls more than 70% of votes through roughly 28.1% of share capital. No direct listing can change that, and no U.S. index fund entry changes the math.

The practical consequence: a direct listing is most likely to take the form of a one-for-one conversion of the ADR into a directly listed B share, not a new share class. That preserves Foundation control, removes the depository layer, and shifts float into U.S.-cleared hands. It also means the dual-class lock-up is permanent, which in turn caps the M&A premium any acquirer could ever pay. Anyone modeling a takeover of Novo Nordisk at a 30% premium needs to subtract the Foundation's super-voting block from the math.

The Danish krone is pegged to the euro through the ERM-2 mechanism, but the residual variance is dominated by Novo Nordisk. When the December 2024 CagriSema readout underwhelmed, the krone weakened the same day. When Novo Holdings — not Novo Nordisk itself — closed its $16.5 billion Catalent acquisition in February 2024, the krone sold off because the Foundation was effectively selling DKK to fund USD. Reuters and Bloomberg have both documented the direct krone–Novo transmission over the past two years.

The macro implication is small but real. Danish GDP runs around DKK 3.0 trillion; Novo Nordisk's market cap, even at the depressed $175 billion (roughly DKK 1.15 trillion), is on the order of 35%–40% of that. A 10% re-rating in the ADR is roughly DKK 115 billion of paper wealth — equivalent to a year of Danish net exports. Currency traders who hedge DKK exposure via Novo Nordisk stock rather than the krone directly will see that channel narrow once the listing changes.

The \"obesity-pill trade\" the headline references has thinned dramatically in the last 12 months. Pfizer discontinued danuglipron in April 2025 over safety concerns, exiting the oral GLP-1 race entirely and leaving its $159 billion market cap without a direct claim on the category. Eli Lilly's Foundayo (orforglipron) — the first daily oral GLP-1 — was FDA-approved in April 2026 and is expected to take roughly 60% of the oral GLP-1 market, or about $13.6 billion, versus Novo's pill at around $4 billion. Structure Therapeutics's aleniglipron posted two positive readouts in late 2025 — its shares more than doubled — but the company remains clinical-stage with no commercial revenue.

Novo Nordisk launched the first GLP-1 pill for obesity, but Eli Lilly's small-molecule design — no food/water restriction, taken any time of day — has reset the bar. On the injectable side, CagriSema's 22.7% weight loss in REDEFINE 1 was a credible number against tirzepatide's 25.5%, but \"credible\" is not what the market wanted. The September 21, 2026 readout of a 14.2% weight-loss figure in REIMAGINE 5 — where 43% of patients hit ≥15% weight loss — restored some narrative around CagriSema in diabetes, but the obesity gap to tirzepatide remains.

While investors debate the direct listing, the more important structural shift has already happened: Novo Holdings — the Foundation's investment arm — completed the $16.5 billion acquisition of Catalent in February 2024 and then sold three fill-finish plants (in Indiana, Italy, and Belgium) directly to Novo Nordisk for $11 billion. Catalent's pre-deal role had been split between Novo and Eli Lilly — a setup that had already prompted a Warren letter to the FTC in October 2024 over reduced competition. Post-deal, those three sites run only Novo Nordisk volume.

Short-term, the direct-listing announcement itself — once it is actually announced rather than hinted — is the catalyst. U.S. institutional ownership of Novo Nordisk at 9.9% versus Eli Lilly's 85.3% is the most directly addressable driver of the 4x P/E gap. Closing even a third of that gap on announcement would imply a ~30–40% re-rating of the ADR — call it a move toward $52, not far from the $46.80 consensus target already on the Street. The structural constraint — Foundation voting lock-up — caps any M&A premium but does not cap a multiple expansion.

Long-term, the listing is a means to an end. The end is surviving Eli Lilly's orforglipron franchise in the obesity-pill category, restarting CagriSema, and protecting a 4-million-plus Wegovy patient base against telehealth-driven copycats and Medicare pricing pressure. A direct listing does not heal those wounds. But it does widen the pool of capital Novo Nordisk can tap without diluting the Foundation's 70%+ voting block — and that, in a Danish company whose controlling shareholder will not sell, is the only acquisition of capital that does not change who is in charge.